Why was the new RSV treatment approved for infants when the evidence suggests it is not safe?

We drafted the article below in early July shortly after Robert F Kennedy Jnr’s new vaccine panel (APIC) made a decision to recommend a new monoclonal antibody treatment for RSV in infants. We had been given access to mortality data from four randomized controlled trials, performed by the manufacturers, that had been undertaken to evaluate the new RSV v…